他汀治疗强度与慢性肾脏病患者死亡率无显著关联
多变量调整后未发现他汀强度与死亡率存在显著关联,支持KDIGO指南推荐使用在CKD人群中研究过的他汀及剂量而非基于强度的给药策略。
要点
- CKD G3a-G4期患者中,他汀治疗强度与全因死亡率无显著关联
- 高强度他汀更多用于近年及确诊动脉粥样硬化性心血管疾病的患者
- 结果支持KDIGO指南推荐使用在CKD人群中研究过的他汀及剂量
核心结论
- 在美国退伍军人CKD G3a-G4期患者中,1年他汀治疗强度与随后4年全因死亡率无显著关联。
- 结果支持KDIGO指南推荐使用在CKD人群中研究过的他汀及剂量,而非基于强度的给药策略。
研究设计与样本
- 回顾性队列研究,纳入2005至2015年美国退伍军人CKD G3a、G3b或G4期且新发持续使用他汀的患者。
- 他汀强度分为低强度(预期LDL-C降低<30%)、中等强度(30%至<50%)和高强度(≥50%),评估初始1年暴露与随后4年全因死亡率的关系。
- 使用Cox比例风险模型,调整人口学特征、合并症和实验室指标。
主要发现
- 高强度他汀在近年及确诊动脉粥样硬化性心血管疾病患者中使用更多。
- 未调整和多变量调整分析中,他汀强度与死亡率均无显著关联。
临床怎么用
- 对于CKD G3a-G4期患者,选择他汀时应优先使用在CKD人群中研究过的药物及剂量,而非依据治疗强度。
- 不应仅因追求高强度他汀而调整CKD患者的降脂方案,需结合循证证据个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2013 American College of Cardiology/American Heart Association lipid guideline recommends statin dosing based on intensity, rather than targeting specific low-density lipoprotein cholesterol (LDL-C) concentrations, among general populations. The 2013 Kidney Disease: Improving Global Outcomes (KDIGO) lipid guideline recommends statins for most adults with chronic kidney disease (CKD), but dose-dependent statin effects in CKD are unclear. METHODS: We performed a retrospective cohort study of US veterans with CKD Stages G3a, G3b or G4, and new, persistent statin use, from 2005 to 2015. We tested the association of intensity of statin therapy [categorized as low (expected LDL-C reduction <30%), medium (30 to <50%) or high (≥50%)] during the initial 1-year exposure period, with all-cause mortality over the subsequent 4 years. We used Cox proportional hazard models to evaluate the association between statin intensity and all-cause mortality, adjusting for demographics, comorbidities and laboratory measurements. RESULTS: Our cohort included 65 292 persons, of whom 40 124 (61.5%) had CKD G3a, 20 183 (30.9%) G3b and 4985 (7.6%) G4. Overall, 4878 (7.5%) used high-intensity, 39 070 (59.8%) used moderate-intensity and 21 344 (32.7%) used low-intensity statins. High-intensity statins were used more in recent years, and among persons diagnosed with atherosclerotic cardiovascular disease. There was no association between statin intensity and mortality in unadjusted or multivariable-adjusted analyses. CONCLUSIONS: There were no significant associations between statin intensity over 1 year of exposure and subsequent mortality among US veterans with CKD. This supports the current KDIGO guideline recommendations to use statins and dosages that have been studied specifically in CKD populations, rather than intensity-based dosing.
引用
- Walther CP, Richardson PA, Virani SS, et al. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020. PMID: 30053252. doi:10.1093/ndt/gfy237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。